The company will publish the clinical study data of the innovation research of OBI-822/OBI-821 for metastatic breast cancer patients at the annual meeting of 2016 ASCO.
2016.May.30
Announcement of the Company holding investor presentation and Significant post press conference
2016.May.30
Company will hold the Investor Conference
2016.May.29
The company states the media’s reports on the related matters of American Society of Clinical Oncology (ASCO).
2016.May.26
Media reports that Michael Chang, the chairman of the company, Amy Huang, the general manager and the staffs, six people in total, were guaranteed pending summons for alleged insider trading.
2016.May.19
Publication of the Breast Cancer Study Abstract to be presented at ASCO 2016
2016.May.13
Board Intentions to apply for long-term fund-raising plan
2016.May.13
Supplementary notice on a company board resolution for the upcoming 2016 Annual Shareholders' Meeting
2016.May.03
Company reports outsider suspected of “rumor mongering” intended to manipulate company’s stock, and plans to take legal action against “NEXT Magazine”
2016.Apr.22
OBI Pharma announces the end of the implementation for its first treasury share buyback program